AbbVie Inc. $ABBV is Duncker Streett & Co. Inc.’s 5th Largest Position

Duncker Streett & Co. Inc. lifted its holdings in AbbVie Inc. (NYSE:ABBV) by 3.7% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 74,644 shares of the company’s stock after purchasing an additional 2,632 shares during the period. AbbVie comprises approximately 3.1% of Duncker Streett & Co. Inc.’s holdings, making the stock its 5th biggest position. Duncker Streett & Co. Inc.’s holdings in AbbVie were worth $16,234,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in ABBV. Brighton Jones LLC lifted its position in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. grew its stake in shares of AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after acquiring an additional 789 shares during the period. Ieq Capital LLC increased its holdings in AbbVie by 4.6% in the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after acquiring an additional 5,274 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC raised its stake in AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after acquiring an additional 612,702 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved TEPKINLY (epcoritamab) plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma, making it the first and only bispecific-based therapy approved in Europe for this setting and expanding AbbVie’s oncology growth opportunity. Article Title
• Positive Sentiment: Cantor Fitzgerald raised its price target on AbbVie to $265 from $240 and reiterated an overweight rating, signaling continued analyst confidence in the stock’s outlook. Article Title
• Neutral Sentiment: Media coverage highlighted AbbVie as a high-yield dividend and “quality, low-stress” healthcare stock, which may support investor sentiment but does not change fundamentals. Article Title
• Negative Sentiment: AbbVie lowered its Q2 2026 EPS guidance to $3.57-$3.61 versus the consensus $3.77, suggesting earnings could come in below expectations. Article Title
• Negative Sentiment: The company also cut full-year 2026 EPS guidance to $13.91-$14.11, below the consensus estimate of $14.25, which may pressure the shares despite recent product wins. Article Title

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Evercore set a $235.00 price target on AbbVie in a report on Friday, May 15th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Bank of America raised AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price target on the stock in a report on Thursday, April 30th. Finally, Wells Fargo & Company set a $260.00 target price on shares of AbbVie in a research note on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.67.

AbbVie Price Performance

Shares of NYSE ABBV opened at $254.71 on Wednesday. The business’s 50 day moving average is $222.39 and its two-hundred day moving average is $220.69. AbbVie Inc. has a 1-year low of $184.63 and a 1-year high of $261.64. The stock has a market capitalization of $450.02 billion, a P/E ratio of 125.47, a PEG ratio of 0.84 and a beta of 0.30.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter last year, the firm earned $2.46 earnings per share. As a group, equities research analysts anticipate that AbbVie Inc. will post 14.28 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is currently 340.89%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.